These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 6893103

  • 1. Requirements of vitamin D metabolites in patients with renal disease.
    Massry SG.
    Am J Clin Nutr; 1980 Jul; 33(7):1530-5. PubMed ID: 6893103
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
    von Herrath D, Kraft D, Schaefer K, Krempien B.
    MMW Munch Med Wochenschr; 1974 Sep 13; 116(37):1573-8. PubMed ID: 4374654
    [No Abstract] [Full Text] [Related]

  • 3. Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.
    Teitelbaum SL.
    Ann Intern Med; 1981 Mar 13; 94(3):404-5. PubMed ID: 6894359
    [No Abstract] [Full Text] [Related]

  • 4. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
    Malluche HH, Goldstein DA, Massry SG.
    Contrib Nephrol; 1980 Mar 13; 18():98-104. PubMed ID: 7353383
    [No Abstract] [Full Text] [Related]

  • 5. Do parathyroid hormone and 1,25-dithydroxyvitamin D modulate bone formation in uremia?
    Teitelbaum SL, Bergfeld MA, Freitag J, Hruska KA, Slatopolsky E.
    J Clin Endocrinol Metab; 1980 Aug 13; 51(2):247-51. PubMed ID: 6893204
    [No Abstract] [Full Text] [Related]

  • 6. Calcitriol in disorders of bone and calcium metabolism.
    Riggs BL.
    Clin Ther; 1980 Aug 13; 3(1):33-9. PubMed ID: 6893296
    [No Abstract] [Full Text] [Related]

  • 7. Short-term effects of 1,25-dihydroxycholecalciferol on disordered calcium metabolism of renal failure.
    Brickman AS, Coburn JW, Norman AW, Massry SG.
    Am J Med; 1974 Jul 13; 57(1):28-33. PubMed ID: 4600292
    [No Abstract] [Full Text] [Related]

  • 8. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD, Malluche HH, Goldstein DA, Singer FR, Massry SG.
    Arch Intern Med; 1980 Aug 13; 140(8):1030-3. PubMed ID: 6893118
    [Abstract] [Full Text] [Related]

  • 9. Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic and failure.
    Eastwood JB, Phillips ME, de Wardener HE, Bordier J, Marie P, Arnaud CD, Norman AW.
    J Urol Nephrol (Paris); 1974 Dec 13; 80(12):984-5. PubMed ID: 4617780
    [No Abstract] [Full Text] [Related]

  • 10. Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure.
    Sherrard DJ, Coburn JW, Brickman AS, Singer FR, Maloney N.
    Contrib Nephrol; 1980 Dec 13; 18():92-7. PubMed ID: 7353382
    [No Abstract] [Full Text] [Related]

  • 11. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
    Brickman AS, Coburn JW, Sherrard DJ, Wong EG, Norman AW, Singer FR.
    Contrib Nephrol; 1980 Dec 13; 18():29-41. PubMed ID: 7353378
    [No Abstract] [Full Text] [Related]

  • 12. [Effect of vitamin D metabolites on mineralization of bone tissue and phosphocalcium metabolism disorders in the course of vitamin D deficiency osteomalacia].
    Bordier P, Miravet L, Marie P, Guéris J, Rousselet F, Norman A, Rasmussen H, Ryckewaert A.
    Rev Rhum Mal Osteoartic; 1978 Apr 13; 45(4):241-8. PubMed ID: 353964
    [No Abstract] [Full Text] [Related]

  • 13. Proceedings: The use of metabolically-active derivatives of vitamin D in rickets and osteomalacia due to renal glomerular failure.
    Smith R, Henderson RG, Russell RG.
    J Bone Joint Surg Br; 1975 May 13; 57(2):247-8. PubMed ID: 1141297
    [No Abstract] [Full Text] [Related]

  • 14. [Clinical significance of vitamin D metabolites].
    Araszkiewicz Z.
    Pol Arch Med Wewn; 1975 Oct 13; 54(4):387-93. PubMed ID: 1187406
    [No Abstract] [Full Text] [Related]

  • 15. Short-term effects of vitamin D3 and 1,25-dihydroxyvitamin D3 on osteomalacia in uremic rats fed a low calcium-low-phosphorus diet.
    Weisbrode SE.
    Am J Pathol; 1981 Jul 13; 104(1):35-40. PubMed ID: 6266257
    [Abstract] [Full Text] [Related]

  • 16. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure.
    Delling G, Lühmann H, Bulla M, Fuchs C, Henning HV, Jansen JL, Kohnle W, Schulz W.
    Contrib Nephrol; 1980 Jul 13; 18():105-21. PubMed ID: 7353369
    [Abstract] [Full Text] [Related]

  • 17. The management of renal osteodystrophy.
    de Wardener HE, Eastwood JB.
    Adv Exp Med Biol; 1977 Jul 13; 81():533-47. PubMed ID: 331902
    [Abstract] [Full Text] [Related]

  • 18. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL, Felsenfeld AJ, Llach F.
    Arch Intern Med; 1983 Jun 13; 143(6):1205-11. PubMed ID: 6344827
    [Abstract] [Full Text] [Related]

  • 19. A skeletal mineralizing defect in dialysis patients: a syndrome resembling osteomalacia but unrelated to viatamin D.
    Coburn JW, Sherrard DJ, Brickman AS, Wong EG, Norman AW, Singer FR.
    Contrib Nephrol; 1980 Jun 13; 18():172-83. PubMed ID: 7353374
    [No Abstract] [Full Text] [Related]

  • 20. Editorial: Azotaemic renal osteodystrophy.
    Med J Aust; 1974 Jun 01; 1(22):864-5. PubMed ID: 4851493
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.